Gilde Healthcare today announces it raised €517 million towards the first and final close of Gilde Healthcare Private Equity IV (GHPE IV). GHPE IV focuses on investments in profitable healthcare companies operating in the lower mid-market in North-west Europe.
The fund concentrates on firms with an active buy-and-build strategy and invests in all sub-segments of the healthcare sector. These include companies in healthcare provision, service providers to the healthcare sector and medical industry, manufacturers of medical supplies and pharmaceutical companies. Market interest was strong and the new fund was oversubscribed, attracting institutional investors from the Netherlands, Germany, United Kingdom, France, Italy, and Scandinavia.
Jasper van Gorp, Managing Partner at Gilde Healthcare and Head of the Private Equity team comments: “With the new fund, we will expand our portfolio with differentiating European growth platforms in the healthcare sector. With our active investment strategy, we are responding to the market’s need for increasing scale, quality improvement and efficiency. Furthermore, our pipeline comprises several attractive new investments in North-west Europe.”
Gilde Healthcare’s mission is to generate attractive returns for its investors by investing in companies that enable better healthcare at lower costs. Gilde Healthcare has two fund strategies under management, focused on the healthcare sector: Private Equity and Venture&Growth.
Pieter van der Meer, co-Founder and Managing Partner at Gilde Healthcare, responsible for fundraising adds: “We are proud of the strong interest in our funds. Increasingly, institutional investors such as pension funds are looking for impactful investments in healthcare. With our investment strategy focused on high-quality and affordable healthcare, we not only realize attractive returns, but we also offer participants the opportunity to invest in companies that enhance the efficiency and accessibility of healthcare.”
In combination with its vintage 2020 transatlantic Venture&Growth fund V, Gilde Healthcare has raised €933 million ($1.0 billion) in capital in less than two years. In the past fifteen years, Gilde Healthcare has made 70 platform investments, of which 46 have been sold or floated. A track record that places Gilde at the top of industry benchmarks.
Recent examples of private equity investments in healthcare include among others the buy-and-builds of Dutch ACE Pharmaceuticals, German cannula manufacturer Acti-Med, Danish clinical research organization Klifo and Dutch contract research organization Symeres, which was recently sold after a successfully executed international expansion strategy in a three-year timeframe.
Gilde Healthcare’s investment team consists of experienced sector experts who have made investments in all segments of the healthcare industry over the past 20 years. The Gilde Healthcare Private Equity IV fund targets companies with an EBITDA of €2 to €15 million.
Media contact:
Jasper van Gorp (Managing Partner)
email: vangorp@gildehealthcare.com
Mob nr: +31.6.11867319
Pieter van der Meer (Managing Partner)
email: vandermeer@gildehealthcare.com
Mob nr: +31.6.54308551
About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with €2 billion in funds raised for two strategies: Private Equity and Venture&Growth. The firm is headquartered in Utrecht (The Netherlands) with local offices in Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Private Equity participates in profitable healthcare companies based in North-west Europe. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medical technology, digital health technology and pharmaceutical development in Europe and North America. More information: www.gildehealthcare.com